---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-019471"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-06-05T23:59:59+00:00"
generated_at: "2026-05-19T22:48:34.606129+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Allarity Therapeutics partners with Indiana Biosciences Research Institute to study stenoparib's dual mechanism

## Summary
- Collaboration aims to clarify contributions of PARP inhibition and WNT pathway modulation to stenoparib's anticancer effects.
- Stenoparib is a dual PARP1/2 and tankyrase1/2 inhibitor currently in Phase 2 trial for advanced ovarian cancer.
- Research may support future marketing approval and potential expansion into colorectal cancer and SCLC combination trial.
- No financial terms of the collaboration were disclosed in the press release.

## SEC filing metadata
- accession: 0001437749-25-019471
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774925019471/0001437749-25-019471-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774925019471/allr20250604_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-019471
- JSON: https://secwatch.observer/filing/0001437749-25-019471.json
- Plain text: https://secwatch.observer/filing/0001437749-25-019471.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.